APT Therapeutics Competitors and Similar CompaniesClear all

APT Therapeutics's competitors and similar companies include UCB, Genentech, Cipla and Alembic Pharmaceuticals.

	APT Therapeutics APT Therapeutics is a drug discovery company developing a therapy for the treatment of thrombotic diseases.	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.	Alembic Pharmaceuticals Alembic Pharmaceuticals is a company that develops, manufactures, and markets pharmaceutical products, pharmaceutical substances, and intermediates
Founding Date	Founding Date 2001	Founding Date 1928	Founding Date 1976	Founding Date 1935	Founding Date 2010
Type	Type Private	Type Public	Type Subsidiary	Type Public	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations St. Louis, US HQ Naperville, US	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more	Locations Vadodara, IN HQ Baska, IN Mumbai, IN Namthang, IN Vadodara, IN Vadodara, IN
Employees	Employees 3	Employees 9,052	Employees 18,077	Employees 27,764	Employees 14,858
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) €7.4b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) ₹277.1b (FY, 2026)	Revenue (est.) ₹73.4b (FY, 2026)
Cost of goods	Cost of goods N/A	Cost of goods €1.4b (FY, 2025)	Cost of goods N/A	Cost of goods ₹95.5b (FY, 2026)	Cost of goods ₹19.8b (FY, 2026)
Gross profit	Gross profit N/A	Gross profit €7.2b (FY, 2025)	Gross profit N/A	Gross profit ₹195b (FY, 2026)	Gross profit ₹54.1b (FY, 2026)
Net income	Net income N/A	Net income €1.6b (FY, 2025)	Net income N/A	Net income ₹38.7b (FY, 2026)	Net income ₹6.7b (FY, 2026)
Operating ⚠
Products	Products N/A	Products N/A	Products N/A	Products 1.5 k (FY, 2024)	Products 145 (FY, 2024)